Cerenovus, part of DePuy Synthes Products, Inc.

Clinical trials sponsored by Cerenovus, part of DePuy Synthes Products, Inc., explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

Medical device company focused on neurovascular care, owned by Johnson & Johnson.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Brain artery block shows promise for stopping migraines Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1 Completed 2

Brain artery block shows promise for stopping migraines

Disease control Recruiting now

This study tests whether blocking a small artery in the brain (the middle meningeal artery) with a special glue can prevent chronic migraines. About 70 adults with hard-to-treat chronic migraine will receive the procedure. The main goal is to see if it safely reduces the number o…

Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Cerenovus, part of DePuy Synthes Products, Inc.

Upcoming readouts

Brain artery block shows promise for stopping migraines